Call 888-776-0942 from 8 a.m. to 10 p.m. Eastern Time

Torrance, California, December 6, 2021/PRNewswire/ - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today According to data from Endari ®, the company’s prescription L-glutamine oral powder for the treatment of sickle cell disease has been accepted at the 63rd American Society of Hematology (ASH) Annual Meeting in Georgia from December 11th to 14th The poster for the exhibition shows the World Convention Center in Atlanta, Georgia, in fact.

Title: Evaluation of blood transfusion data from a phase 3 clinical study of L-glutamine in sickle cell disease Moderator: Hung Lam, PhD1 Authors: Hung Lam, PhD1*, Joseph M Becerra, PharmD2, Charles W Stark, PharmD2*, Yutaka Niihara , MD2 and Michael Callaghan, MD3 1MMS Holdings, Canton, MI; 2 Emmaus Medical, Inc., Torrance, CA; 3 Hematology/Oncology Project, Detroit Children’s Hospital, Michigan: Oral and Poster Abstract Session: 114. Hemoglobinopathy, No Including Thalassemia: Clinical and Epidemiology: Poster III Date: Monday, December 13, 2021, 6:00 pm-8:00 pm Eastern Time Location: Georgia World Congress Center Hall B5

The abstract can also be accessed on the "Research Publications" page of the Emmaus website: https://www.emmausmedical.com/content/pipeline/researchpub/research-publications-210 

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and a leader in the treatment of sickle cell disease. The company currently sells Endari® (L-glutamine oral powder) approved by the U.S. Food and Drug Administration to reduce acute complications of sickle cell disease in adults and children 5 years and older. The company is also committed to discovering and developing innovative therapies and therapies for certain rare and rare diseases and diseases that affect a larger population (such as diverticulosis). For more information, please visit www.emmausmedical.com.

About Endari® (prescription grade L-glutamine oral powder) Endari® is Emmaus' prescription grade L-glutamine oral powder, which was approved by the FDA in July 2017 for the treatment of adult and pediatric patients aged 5 years and older. Sickle cell disease. Endari® began to be sold in the United States in 2018.

Indications Endari® is used to reduce acute complications of sickle cell disease in adults and children aged 5 years and older.

Important safety information The most common adverse reactions in clinical studies (incidence> 10%) are constipation, nausea, headache, abdominal pain, cough, pain in limbs, back pain, and chest pain.

Adverse reactions leading to treatment interruption included 1 case each of hypersplenism, abdominal pain, indigestion, burning sensation and hot flashes.

The safety and effectiveness of Endari in pediatric patients with sickle cell disease under 5 years of age have not been established.

For more information, see Endari's full prescribing information: www.ENDARIrx.com/PI.

About sickle cell disease About 100,000 people in the United States have sickle cell disease (SCD), and there are millions more worldwide. The sickle gene exists in every ethnic group, not just among people of African descent. In the United States, it is estimated that one in 365 African Americans and 16,300 Hispanic Americans was born with SCD. 1 The genetic mutation that causes SCD causes an individual's red blood cells to deform into a "C" or sickle shape, reducing their ability to transport oxygen throughout the body. These sickle-shaped red blood cells decompose rapidly, become very viscous, and have a tendency to clump together, causing them to get stuck in blood vessels and cause damage. The result is a decrease in blood flow to remote organs, leading to physical symptoms such as pain, tissue and organ damage, and premature death. 2

1 Source: data and statistics on sickle cell disease-National Center for Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, December 2020. 2 Source: Committee on Addressing Sickle Cell Disease-Strategic Plan and Blueprint for Action-National Academy of Sciences Press, 2020.

Source: Emmaus Life Sciences, Inc.

More news releases on similar topics

Cision Distribution 888-776-0942 8 a.m. to 9 p.m. Eastern Time